Daiichi Sankyo
Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)
Company Overview
Daiichi Sankyo is one of Japan's largest pharmaceutical companies and a global leader in antibody-drug conjugate (ADC) technology. The company's partnership with AstraZeneca on Enhertu has produced one of the most successful cancer drugs in recent history. Daiichi Sankyo's ADC pipeline represents a new paradigm in targeted cancer therapy.
セクター
主要市場
この企業が重要な理由
Daiichi Sankyo's ADC platform has established Japan as a global leader in next-generation cancer therapeutics, with a pipeline valued at tens of billions of dollars.
主要注力分野
Antibody-Drug ConjugatesOncologyRare DiseasesVaccines
同業他社
Signal Timeline
0 件No signals tracked yet for this company.
Signals will appear here as official announcements are indexed.
この企業の公式チャネルを監視中です。シグナルが発見され次第表示されます。
Daiichi Sankyoのシグナル更新を受け取る
この企業の新しいシグナルが公開されたら通知を受け取る。